Table 3.
Characteristics of included prognostic effect (Survival rate) studies in the meta-analysis.
| Survival rate (one- and two-year) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| First author (Year of publication) | Country | Design of the study | Settings | Population | Female % | S100B cutoff (µg/L) | S100B methods | LDH cutoff (IU/L) | LDH methods | Total number of patients |
| Weide et al., 2012 (47) | Germany | prospective | multicenter | Resectable and nonresectable stage IV | 43.6 | 0.15; 0.10 | Sangtec® 100 ELISA, Elecsys® S100 | ULN | automated colourimetric assay | 855 |
| Weide et al., 2013 (48) | Germany | prospective | multicenter | Nonresectable stage IV with first-line systemic therapy | 41.5 | 0.15; 0.10 | Sangtec® 100 ELISA, Elecsys® S100 | ULN | automated colourimetric assay | 499 |
| Weide et al., 2016 (49) | Germany | prospective | multicenter | Nonresectable stage IV | 41.3 | 0.10 | Elecsys® S100 | 250 | automated colourimetric assay | 206 |
| Amaral, Kiecker et. al., 2020 (50) | Germany | retrospective | multicenter | Nonresectable stage IV (brain metastasis) with combined immunotherapy | 36.8 | 0.11 | Elecsys® S100 | 250 | automated colourimetric assay | 380 |
SLN, sentinel lymph node; ULN, upper limit normal; N.R., not reported.